A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban

Blood Coagul Fibrinolysis. 2020 Sep;31(6):405-409. doi: 10.1097/MBC.0000000000000929.

Abstract

: Hereditary protein S deficiency is an autosomal dominant disorder associated with a high risk of venous thromboembolism (VTE) and usually results from mutations of PROS1. Historically heparin and warfarin have been applied as recommended treatment of VTE. Recent researches showed that rivaroxaban provided more consistent and predictable anticoagulation than warfarin. However, it is unknown whether rivaroxaban is effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report two cases of recurrent VTE in two patients with hereditary protein S deficiency, owing to the same nonsense mutation in PROS1, which were successfully treated by rivaroxaban monotherapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Factor Xa Inhibitors / therapeutic use*
  • Humans
  • Male
  • Protein S / genetics
  • Protein S Deficiency / complications*
  • Protein S Deficiency / genetics
  • Rivaroxaban / therapeutic use*
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology*
  • Venous Thromboembolism / genetics

Substances

  • Factor Xa Inhibitors
  • PROS1 protein, human
  • Protein S
  • Rivaroxaban